# Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-1

> **NCT02600611** · PHASE3 · COMPLETED · sponsor: **Motif Bio** · enrollment: 600 (actual)

## Conditions studied

- Skin Structures and Soft Tissue Infections

## Interventions

- **DRUG:** iclaprim
- **DRUG:** vancomycin

## Key facts

- **NCT ID:** NCT02600611
- **Lead sponsor:** Motif Bio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-01
- **Primary completion:** 2017-01-30
- **Final completion:** 2017-01-30
- **Target enrollment:** 600 (ACTUAL)
- **Last updated:** 2018-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02600611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02600611, "Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-1". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02600611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*